Tremfya (Guselkumab) Denied by Insurance: Appeal

Tremfya (guselkumab) is an IL-23 inhibitor biologic developed by Janssen (Johnson & Johnson), FDA-approved for moderate-to-severe plaque psoriasis and active psoriatic arthritis. Tremfya works by selectively blocking IL-23, a cytokine that drives the inflammatory cascade responsible for psoriatic skin plaques and joint disease. In clinical trials, Tremfya demonstrated high rates of skin clearance (PASI 90 and PASI 100 responses) and sustained efficacy out to five years. Despite this clinical record, patients seeking Tremfya coverage routinely face insurance denials rooted in cost-control mechanisms — primarily step therapy and Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization.

Why Insurance Denies Tremfya

Step therapy requiring conventional and TNF therapy first is the most common denial reason. Most insurers require patients to try and fail conventional systemic medications — methotrexate, cyclosporine, or apremilast — before approving any biologic for psoriasis. Then, as a newer IL-23 inhibitor, Tremfya may face a second step therapy requirement demanding prior failure of a TNF inhibitor (such as adalimumab or etanercept) before it is approved. This two-tier step therapy protocol can delay access to an effective treatment by a year or more.

Prior authorization is mandatory. Tremfya's PA process requires: confirmed diagnosis of moderate-to-severe plaque psoriasis or active PsA, documentation of prior treatment failure, disease severity assessment, and physician certification that Tremfya is medically appropriate.

PASI score requirements create a severity threshold that some plans apply strictly. Insurers may require a baseline PASI score of 12 or higher, or BSA involvement of 10% or more, to establish that disease qualifies as moderate-to-severe. Patients with disease that is not widespread by body surface area but is severely affecting visible areas (face, hands, genitalia) or significantly impairing quality of life may be denied on purely numerical grounds.

Preferred formulary alternatives are a denial trigger when a plan's preferred biologic is a different IL-23 inhibitor (such as Skyrizi or Ilumya) or a different class entirely. The plan will deny Tremfya without a formulary exception demonstrating that a preferred alternative is not clinically appropriate for the specific patient.

PsA-specific denial patterns occur when Tremfya is prescribed for psoriatic arthritis and the insurer's PA criteria for PsA biologics differ from their psoriasis criteria — sometimes requiring additional DMARD failure documentation or different disease activity scoring.

How to Appeal a Tremfya Denial

Document your PASI and DLQI scores. PASI (Psoriasis Area and Severity Index) and DLQI (Dermatology Life Quality Index) scores are the primary objective measures insurers use to confirm moderate-to-severe disease. Your dermatologist should record these scores at the time of Tremfya prescription. A PASI score of 12 or higher, BSA of 10% or more, or DLQI of 10 or higher are commonly accepted thresholds, but even patients with lower scores can qualify if disease affects a particularly impactful body area.

Provide a full prior treatment history. List every systemic medication you have tried for psoriasis: drug name, start date, end date, maximum dose, and reason for discontinuation. Include documented adverse effects (such as liver toxicity from methotrexate, bone marrow suppression, or kidney toxicity from cyclosporine) as reasons for conventional therapy failure. Include any biologics previously tried and why they failed, using disease activity records from those treatment periods.

Highlight the clinical rationale for Tremfya. If your dermatologist chose Tremfya specifically (over another biologic) for a clinical reason — such as prior TNF secondary failure, safety concerns with other agents, or clinical characteristics suggesting a better response to IL-23 inhibition — this should be stated explicitly in the medical necessity letter.

For PsA appeals: Provide joint count assessments (tender and swollen joint counts), DAS28 scores if available, and documentation of DMARD failure (typically methotrexate). Imaging showing joint damage or sacroiliitis may also support the appeal.

Pursue a step therapy override. Many states have enacted laws requiring insurers to grant step therapy exceptions when a physician certifies that the required first-line drug is contraindicated, previously failed, or likely to cause adverse effects. Have your dermatologist or rheumatologist file a formal step therapy exception request and provide the clinical documentation to support it.

Request peer-to-peer review. A dermatologist or rheumatologist speaking directly with the insurer's medical reviewer frequently resolves step therapy denials that do not resolve through written appeals alone.

Patient Assistance Programs

Janssen offers Janssen CarePath, a patient support program that includes copay assistance for commercially insured patients (reducing out-of-pocket costs significantly) and a free drug program for uninsured or underinsured patients. Visit janssencarepath.com or call 1-877-CarePath (1-877-227-3728).

Tremfya is administered by injection every 8 weeks (after initial doses), and its list price is approximately $25,000–$30,000 per year. Patient assistance programs are critical for maintaining access while an appeal is pending.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.

Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• What Is Step Therapy?